NLRP3 inhibitors: Unleashing their therapeutic potential against inflammatory diseases

• Published in: Biochemical pharmacology Vol. 218; p. 115915
• Main Author: Ramalingam, Vaikundamoorthy
• Format: Journal Article
• Language: English
• Published: England 01.12.2023
• Subjects: Cytokines; Humans; Inflammasomes - metabolism; Inflammation - drug therapy; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Molecular targets; NLRP3 inflammasome; Clinical development; Natural products; Synthetic drugs
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2023.115915

The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome has been linked to the release of pro-inflammatory cytokines and is essential for innate defence against infection and danger signals. These secreted cytokines improve the inflammatory response caused by tissue damage and associated inflammation. Consequently, the development of NLRP3 inflammasome inhibitors are viable option for the treatment of diverse inflammatory disorders. The significant anti-inflammatory effects of the NLRP3 inhibitors have severe side effects. Hence, the application of NLRP3 inhibitors against inflammatory disease has not yet been understood and most of the developed inhibitors are unsuccessful in clinical trials. The processes behind the NLRP3 complex, priming, and activation are the main emphasis of this review, which also covers therapeutical inhibitors of the NLRP3 inflammasome and potential therapeutic strategies for directing the NLRP3 inflammasome towards clinical development.